Stock market today: S&P 500 ends lower, but tech bounce on dip-buying stems losses
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, announced Thursday it has purchased 445,321 of its ordinary shares at a price of 28 pence per share. The shares will be held in treasury, according to a company statement.
The share buyback was executed in two transactions on Wednesday, with 313,321 shares purchased at 11:09 a.m. and 132,000 shares at 4:48 p.m., both on the AIM market of the London Stock Exchange.
Following the purchase, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 4,020,366 held in treasury. The total number of voting rights in the company now stands at 445,073,424.
As part of the buyback, EKF acquired 132,000 shares from investment funds managed by Harwood Capital, with 44,000 shares from Oryx International Growth Fund Limited and 88,000 shares from North Atlantic Smaller Companies Investment Trust PLC. The company noted that this transaction was facilitated to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director, remains at approximately the same level and does not exceed 30% of the company’s total voting rights.
Following the transaction, Mills’ aggregate indirect interest in the company is 131,246,000 ordinary shares.
EKF Diagnostics operates five manufacturing sites across the US and Germany and sells into over 120 countries worldwide, focusing on point-of-care analyzers in hematology and diabetes, as well as life sciences services.
The information was disclosed in a regulatory announcement based on a company press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.